Replies to post #23 on Short Ideas

[CHM_760]

To be honest, I wasn't too crazy about the Kevetrin PR this morning.. but 20% later, how can I really complain?

I'm also not too sure about the wording of "the Principal Investigators for the Kevetrin trial have requested that the Company start preparing a presentation to be used for an article on the safety and pharmacological effect of Kevetrin on multiple cancer lines as demonstrated in the clinical trial". In my experience, the principal investigators would want to release any data in a peer-reviewed journal, and not a "presentation" or an "article".

I guess I'm just being too judgmental, but have been burned before by small biotechs getting ahead of themselves on releasing anecdotal results.